August 5

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests

SE Asia Latest Target Market in Growing Global Distributor Network

MedMira Inc., (\"MedMira\") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it has expanded its global distribution network into Southeast Asia, where the Company\'s MiraWell(R) Rapid HIV Test (MiraWell HIV) will soon be available to healthcare providers and their patients.

American Health Diagnostics LLC (AHD), a MedMira distribution agent in the United States, has signed an exclusive distribution agreement for MiraWell HIV in select markets of the Southeast Asia region. Under the terms of the agreement AHD will purchase one million MiraWell HIV tests in the first year. Technical training is slated to begin in August 2008 with product sales ramping up throughout the year. AHD is working with its on-the-ground sub-distributors, to market, sell and promote MiraWell HIV in the territory. \"Southeast Asia holds exciting market opportunities for MedMira and we are very pleased to extend our reach into this target region through the AHD channel,\" said Hermes Chan, President and CEO of MedMira. \"Over the past five years, we have worked closely with AHD to support Cardinal Health in successfully marketing and selling our Reveal(R) G3 HIV test in the United States. Based on this model, we look forward to working with AHD and their sub-distribution partners to build a strong market base for MiraWell HIV and additional MedMira products in the future.\"

MiraWell HIV is built on the Company\'s patented rapid flow-through technology platform, which is the product engine behind MedMira\'s successful line of rapid HIV tests that have been approved in Canada, the United States, the European Union, China, Russia, and India. MiraWell HIV is approved by China\'s State Food and Drug Administration (SFDA). The test requires no specialized training or equipment to perform, and uses a whole blood, serum or plasma specimen to deliver results in just three minutes. MiraWell HIV has an extended shelf-life with no refrigeration required, making it ideally suited for all types of testing environments. All of MedMira\'s tests are manufactured in Canada under ISO and GMP standards.

\"Our relationship with MedMira and experience with its products has been excellent and we are confident that MiraWell HIV answers the need for quality rapid diagnostics in the target market,\" said Brian Banks, President of AHD. \"We are excited to be working with our distribution partners who have the strength and experience needed to successfully penetrate the target market and establish a solid end-user customer base for the MiraWell HIV test.\"

According to the WHO\'s 2006 Global Report on AIDS (www.who.int), South and Southeast Asia combined have approximately 7.6 million people living with HIV/AIDS. The reported prevalence of the disease varies widely from country to country.

About American Health Diagnostics

American Health Diagnostics brings innovations to life through a proprietary market readiness process and proven distribution management network. The AHD market readiness and distribution management system has been utilized to introduce MedMira\'s Reveal(R) Rapid HIV-1 Antibody Test the market\'s fastest FDA approved HIV test and ThyroTec\'s ThyroTest(TM), the first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening device. www.ahpartners.com

About MedMira

MedMira is a leading developer, manufacturer, and marketer of advanced rapid diagnostics. Built on the Company\'s patented rapid flow-through technology platform, MedMira\'s single and multiple rapid tests provide hospitals, labs, clinics and individuals around the world with reliable, diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company\'s tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets, have achieved regulatory approvals in Canada, the United States, China, Russia, India, and the European Union. MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).

In 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on biosensor technology platforms. For more information visit www.maplebio.com.

MedMira\'s corporate offices, R&D, and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira\'s website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company\'s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E

SOURCE: MedMira Inc.

Dr. James Smith, Investor Relations & Corporate Affairs, (902) 450-1588, This email address is being protected from spambots. You need JavaScript enabled to view it.